TY - JOUR
T1 - The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
AU - Mishima, Yuji
AU - Paiva, Bruno
AU - Shi, Jiantao
AU - Park, Jihye
AU - Manier, Salomon
AU - Takagi, Satoshi
AU - Massoud, Mira
AU - Perilla-Glen, Adriana
AU - Aljawai, Yosra
AU - Huynh, Daisy
AU - Roccaro, Aldo M.
AU - Sacco, Antonio
AU - Capelletti, Marzia
AU - Detappe, Alexandre
AU - Alignani, Diego
AU - Anderson, Kenneth C.
AU - Munshi, Nikhil C.
AU - Prosper, Felipe
AU - Lohr, Jens G.
AU - Ha, Gavin
AU - Freeman, Samuel S.
AU - Van Allen, Eliezer M.
AU - Adalsteinsson, Viktor A.
AU - Michor, Franziska
AU - San Miguel, Jesus F.
AU - Ghobrial, Irene M.
N1 - Publisher Copyright:
© 2017 The Authors
PY - 2017/4/4
Y1 - 2017/4/4
N2 - The development of sensitive and non-invasive “liquid biopsies” presents new opportunities for longitudinal monitoring of tumor dissemination and clonal evolution. The number of circulating tumor cells (CTCs) is prognostic in multiple myeloma (MM), but there is little information on their genetic features. Here, we have analyzed the genomic landscape of CTCs from 29 MM patients, including eight cases with matched/paired bone marrow (BM) tumor cells. Our results show that 100% of clonal mutations in patient BM were detected in CTCs and that 99% of clonal mutations in CTCs were present in BM MM. These include typical driver mutations in MM such as in KRAS, NRAS, or BRAF. These data suggest that BM and CTC samples have similar clonal structures, as discordances between the two were restricted to subclonal mutations. Accordingly, our results pave the way for potentially less invasive mutation screening of MM patients through characterization of CTCs.
AB - The development of sensitive and non-invasive “liquid biopsies” presents new opportunities for longitudinal monitoring of tumor dissemination and clonal evolution. The number of circulating tumor cells (CTCs) is prognostic in multiple myeloma (MM), but there is little information on their genetic features. Here, we have analyzed the genomic landscape of CTCs from 29 MM patients, including eight cases with matched/paired bone marrow (BM) tumor cells. Our results show that 100% of clonal mutations in patient BM were detected in CTCs and that 99% of clonal mutations in CTCs were present in BM MM. These include typical driver mutations in MM such as in KRAS, NRAS, or BRAF. These data suggest that BM and CTC samples have similar clonal structures, as discordances between the two were restricted to subclonal mutations. Accordingly, our results pave the way for potentially less invasive mutation screening of MM patients through characterization of CTCs.
UR - http://www.scopus.com/inward/record.url?scp=85017021051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017021051&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2017.03.025
DO - 10.1016/j.celrep.2017.03.025
M3 - Article
C2 - 28380360
AN - SCOPUS:85017021051
SN - 2211-1247
VL - 19
SP - 218
EP - 224
JO - Cell Reports
JF - Cell Reports
IS - 1
ER -